GLP-1 for Sleep Apnea: SURMOUNT-OSA Data and Why Zepbound Became the First Approved OSA Drug

For decades, the only "real" treatment for obstructive sleep apnea was CPAP — a positive airway pressure machine worn nightly. The FDA changed that on December 20, 2024 when it approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe OSA in adults with obesity. The pivotal trial — SURMOUNT-OSA — showed tirzepatide reduced the apnea-hypopnea index by 25–29 events/hour, with 42–50% of patients reaching remission or only mild OSA at one year.

Direct answer: Zepbound (tirzepatide) is the only FDA-approved GLP-1 for OSA, and it is approved only in adults with both moderate-to-severe OSA and obesity (BMI ≥30). In the SURMOUNT-OSA Phase 3 trial (469 participants, 52 weeks), tirzepatide reduced breathing disruptions by 25 events/hour off CPAP and 29 events/hour on CPAP, vs ~5–6 events/hour on placebo. 42% of patients off CPAP and 50% on CPAP reached remission or only mild OSA. Mean weight loss was 18–20% of body weight (45–50 lb) vs 2% (4–6 lb) on placebo. The benefit is largely driven by weight loss; CPAP remains the gold standard but tirzepatide adds to or sometimes replaces it.

Why GLP-1s Affect Sleep Apnea

Obstructive sleep apnea is caused by soft tissue at the back of the throat collapsing during sleep. The largest single risk factor is obesity — particularly fat around the neck, tongue, and pharyngeal walls. Reducing that fat shrinks airway tissue and reduces collapse.

GLP-1 medications drive weight loss, which:

• Reduces neck circumference and tongue volume
• Decreases parapharyngeal fat
• Improves diaphragm function
• Reduces ventilatory instability

Direct anti-inflammatory effects on upper airway tissue are likely a secondary mechanism, but most of the OSA benefit tracks closely with how much weight is lost.

SURMOUNT-OSA: The Trial Behind the Approval

Lilly's SURMOUNT-OSA program enrolled 469 adults with moderate-to-severe OSA (AHI ≥15 events/hour) and obesity (BMI ≥30). Randomization was 1:1 to tirzepatide (max tolerated dose, 10 mg or 15 mg) or placebo in two parallel studies:

• Study 1: Adults not using PAP therapy (unable or unwilling to)
• Study 2: Adults already using PAP therapy and planning to continue

Both arms ran 52 weeks.

Headline Results

For context, an AHI reduction from severe (≥30/hour) into mild (<15/hour) is the threshold where most patients can come off CPAP. Roughly half of treated patients hit that threshold.

Effect Size

Tirzepatide was about 5× more effective than placebo at reducing breathing disruptions in patients not on PAP therapy.

Side Effects in the Trial

GI side effects dominated, consistent with other tirzepatide trials:

• Diarrhea, nausea, vomiting, constipation
• Most events mild-to-moderate
• <5% discontinued for side effects
• No new safety signals specific to the OSA population

Who Qualifies for Zepbound for OSA

The FDA label limits use to:

• Adults age 18+
• Moderate-to-severe OSA (AHI ≥15 events/hour)
• Obesity (BMI ≥30)

Tirzepatide is not approved for OSA in non-obese patients, even if their sleep apnea is severe. Anatomical OSA (large tonsils, retrognathia, narrow palate) without obesity gets less benefit from weight loss.

The label also specifies that Zepbound should not be combined with other tirzepatide products or other GLP-1 receptor agonists.

Dosing for OSA

The approved OSA dosing matches the obesity dosing:

• Start at 2.5 mg once weekly
• Increase every 4 weeks: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
• Maintenance: 10 mg or 15 mg weekly, whichever is best tolerated

Most patients reach 10 or 15 mg by week 20–24 if titration is uncomplicated.

Tirzepatide vs CPAP

CPAP works for almost everyone who tolerates it. The problem is tolerance — many patients use it inconsistently or abandon it entirely. Tirzepatide is not framed as a CPAP replacement but as an option for:

The SURMOUNT-OSA on-PAP arm specifically shows that adding tirzepatide to CPAP is additive, not redundant.

What About Semaglutide?

Semaglutide produces less weight loss than tirzepatide at top doses, and Wegovy is not FDA approved for OSA. Real-world data shows semaglutide also reduces AHI through weight loss, but:

• The dedicated OSA trial data are not as strong
• An indication has not been pursued
• Tirzepatide's larger weight loss likely translates to a bigger airway benefit

If a patient is already on semaglutide for weight loss and has OSA, the OSA may improve — but it is not the labeled indication.

What About Retatrutide?

Phase 3 trials of retatrutide include OSA endpoints. Given its larger weight loss (~24% in Phase 2), an even larger AHI reduction is plausible. Approval for OSA is likely some years out.

How Long Until Sleep Apnea Improves?

Improvement tracks with weight loss. A reasonable timeline:

• Weeks 1–4: Minimal change — weight loss is starting but airway tissue hasn't reorganized
• Months 2–4: Snoring often improves first; AHI starts dropping
• Months 6–9: Most of the AHI improvement happens here, matching peak weight loss rate
• Month 12: Plateau — time to repeat a sleep study to see if OSA has remitted

CPAP pressure settings often need to be reduced during this period — keep the sleep specialist in the loop.

Insurance Coverage

OSA approval has improved coverage for many patients who couldn't get Zepbound covered for obesity alone. As of mid-2026:

• Many commercial plans now reimburse Zepbound when prescribed for OSA + obesity
• Medicare coverage for tirzepatide-for-OSA is improving but inconsistent
• Pre-authorization typically requires a documented sleep study with AHI ≥15

What People Get Wrong

• "Any GLP-1 will treat sleep apnea." Only tirzepatide (Zepbound) is FDA approved.
• "It replaces CPAP." Sometimes, eventually. Often, it complements CPAP and may eventually allow weaning.
• "I can use it for OSA at any BMI." No — approval requires both moderate-to-severe OSA and BMI ≥30.
• "My snoring improved, so my apnea is gone." Snoring is a symptom; AHI is the diagnostic. Repeat the sleep study before stopping CPAP.
• "Wegovy works for OSA too." Semaglutide may help via weight loss but is not FDA approved for OSA.

Frequently Asked Questions

Which GLP-1 is approved for sleep apnea? Only Zepbound (tirzepatide). FDA approval was granted on December 20, 2024.

How much does tirzepatide improve sleep apnea? Average AHI reduction was 25 events/hour without CPAP and 29 events/hour with CPAP in the SURMOUNT-OSA trial.

Can I stop CPAP if my AHI improves? Only after a repeat sleep study confirms remission or mild OSA. Your sleep specialist makes that call.

Do I have to have obesity to qualify? Yes. FDA approval requires moderate-to-severe OSA in adults with obesity (BMI ≥30).

Does Wegovy work for sleep apnea? It probably helps via weight loss, but it is not FDA approved for OSA.

How fast does sleep apnea improve on tirzepatide? Most improvement happens between months 3 and 9 as weight loss peaks. Final assessment is at month 12 with a repeat sleep study.

What was the weight loss in the SURMOUNT-OSA trial? About 18% of body weight (~45 lb) for patients not on CPAP and 20% (~50 lb) for patients also on CPAP, vs 2% on placebo.

Last reviewed: May 13, 2026

Sources

• FDA Approves Tirzepatide for Obstructive Sleep Apnea — Pharmacy Times
• Zepbound approved by FDA as first sleep apnea medication — AASM
• FDA approves Zepbound (tirzepatide) for moderate-to-severe OSA — Eli Lilly investor release